Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry

• Published in: Rheumatology and therapy. Vol. 10; no. 1; pp. 187 - 199
• Main Authors: Bergman, Martin J., Zueger, Patrick, Patel, Jayeshkumar, Saffore, Christopher D., Topuria, Ia, Cavanaugh, Cristi, Fang, Siran, Clewell, Jerry, Ogdie, Alexis
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.02.2023; Springer Nature B.V; Adis, Springer Healthcare
• Subjects: Administrative claims; Ankylosing spondylitis; Clinical medicine; Costs; Disease control; Disease registry; Economic burden; Emergency medical care; Family Medicine; General Practice; Health care expenditures; Health care policy; Healthcare resource utilization; Internal Medicine; Medicine; Medicine & Public Health; Original Research; Orthopedics; Pain; Patients; Psoriatic arthritis; Quality of Life Research; Remission (Medicine); Rheumatology; Disease registry; Economic burden; Healthcare resource utilization; Administrative claims; Disease control; Ankylosing spondylitis; Psoriatic arthritis

Background There is limited evidence on the clinical and economic benefit of achieving disease control in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), thus we aimed to assess the impact of disease control on healthcare resource use (HCRU) and direct medical costs among US patients with...